You are here

Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Baltimore, Maryland, 21201-1524 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Bacteremia, Gram-Positive Bacterial Infections
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- To be eligible for this study, a patient must provide informed consent and must meet
all of the following criteria. No study procedures, including any baseline tests,
should be performed until the patient (or parent/legally acceptable representative, if
appropriate) legally signs the informed consent form.

- Male or female, 18 years of age or older and >= 40 kg body weight

- End-stage renal disease patients on hemodialysis with: A) Signs and symptoms of a
localized catheter-related infection (eg tenderness and/or pain, erythema, swelling,
purulent exudates within 2 cm of entry site); OR B) A body temperature of >= 38.0 C or
isolate is S. aureus, it must be cultured from at least 1 culture bottle from either
the peripheral set or the catheter set of culture bottles. For all other Gram-positive
pathogens (eg, coagulase-negative staphylococci), isolates need to be cultured from at
least 2 culture bottles of which one must be from the peripheral set. There must be no
other obvious source of the bacteremia

- Presence of at least one of the following systemic signs of infection (may be obtained
up to 24 hours prior to baseline): *Hypotension, defined as systolic blood pressure
= 40 mmHg from the patient's baseline, in the absence of
other causes for hypotension; *Tachycardia defined as a pulse rate > 90 beats per
minute; *Tachypnea defined as a respiratory rate > 20 breaths per minute or PACO2 torr; *White blood count >10,000 cells/mm3 or differential count showing >10% band neutrophil forms.

- Patients on hemodialysis with tunneled or nontunneled catheters including antibiotic
coated hemodialysis catheters. Patients may have more than one concurrent catheter.

- Patients who are willing and able to comply with scheduled visits, treatment plan,
laboratory tests and other study procedures

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients presenting with any of the following will not be included in this study:

- Catheter-related bloodstream infections caused by Gram-negative bacteria, fungi, mixed
cultures of Gram negative bacteria and Gram positive bacteria or mixed cultures of
Gram positive/negative bacteria and fungi

- Patients with evidence of other infections resulting in bacteremia, such as clinical
or radiographic signs of osteomyelitis, endocarditis, skin/skin structure infection,
pneumonia, urinary tract infection, joint infection, intraabdominal infection, septic
thrombophlebitis or other infection

- Patients in whom the infected catheter cannot be removed

- Patients with permanent intravascular devices such as artificial vascular grafts,
implantable pacemakers or defibrillators; intra-aortic balloon pumps, and left
ventricular assist device; intravascular transplants such as prosthetic cardiac
valves; or non-intravascular devices such as peritoneal dialysis catheters; or
neurosurgical devices such as ventriculo-peritoneal shunts, intra-cranial pressure
monitors, or epidural catheters, prosthetic cardiac valves, prosthetic vascular
grafts, or other internal prosthesis

- Females of child-bearing potential who are unable or unwilling to take adequate
contraceptive precautions, have a positive pregnancy result within 24 hours prior to
study entry, are known to be pregnant, or are currently breastfeeding an infant

- Identification of a pathogen resistant to linezolid or vancomycin

- Patients who are unlikely to survive through the treatment period and evaluation

- Administration of a glycopeptide antibiotic within 5 days prior to enrollment.
Administration of other potentially effective systemic Gram-positive antibiotics for
more than 48 hours within 72 hours prior to enrollment unless the pathogen showed drug
resistance

- Previous enrollment in this protocol

- Hypersensitivity to linezolid, vancomycin, gentamicin or one of their excipients (or
aztreonam if non-bacteremic Gram-negative coverage is required)

- Concurrent use of another investigational medication or use within 30 days of study
entry

- Patients with pressor and fluid-resistant hemodynamic compromise or pulmonary embolism

NCT00108433
Pfizer
Terminated
Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now